← board
CRLBF
distress 2/10 · well-funded / low risk$0.710%today-63% from 52w high
Revenue
$656M
Liquidity
$58M
Runway
—
Shares 1y
—
Price & events
-40.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
-4.0%
1W
-7.8%
1M
-23.6%
3M
-43.2%
6M
+17.2%
1Y
-59.0%
2Y
-93.3%
5Y
-93.2%
All
Overview
- Volume
- 8.40K
- 52 Week Range
- $0.53 – $1.92
- Float Shares
- 345.56M
- % Held by Insiders
- 2.06%
- % Held by Institutions
- 3.51%
- RVOL
- 0.02x
- Beta
- 1.72
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $2 (+182% upside) · 1 analysts
- 2024-08-12NeedhamHold
Competitors
- none identified
Recent news
- 2026-07-13Cresco Labs to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire
- 2026-07-13Cresco Labs to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Globe and Mail
- 2026-07-13Cresco Labs to report Q2FY26 results on August 6, 2026 - scanx.trade
- 2026-07-05Cresco Labs holds the spotlight on cannabis strategy - Ad-hoc-news.de
- 2026-06-21Cresco Labs Stock - Sunday background on the cannabis operator - Ad-hoc-news.de
- 2026-06-20Cresco Labs Stock - Long-term strategy in a shifting US cannabis market - Ad-hoc-news.de
- 2026-06-11Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock? - Yahoo Finance
- 2026-06-08Cresco Labs Closes US$50 Million Revolving Credit Facility with Needham Bank - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.